|
|
| | Erlotinib D6 HCl Basic information |
| Product Name: | Erlotinib D6 HCl | | Synonyms: | Erlotinib D6;Erlotinib Hydrochloride Impurity G;[2H6]-Erlotinib Hydrochloride;CP-358774 D6 hydrochloride;NSC 718781 D6 hydrochloride;OSI-774 D6 hydrochloride;Erlotiniβ-d6 Hydrochloride | | CAS: | 1189953-78-3 | | MF: | C22H18ClD6N3O4 | | MW: | 435.933630668 | | EINECS: | | | Product Categories: | | | Mol File: | 1189953-78-3.mol |  |
| | Erlotinib D6 HCl Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: slightly, heated,Methanol: slightly soluble | | form | A solid |
| | Erlotinib D6 HCl Usage And Synthesis |
| Description | Erlotinib-d6 (hydrochloride) contains six deuterium atoms located on the methoxy group. It is intended for use as an internal standard for the quantification of erlotinib by GC- or LC-MS. Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma (HN5) tumor xenografts in mice with an ED50 value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F (IC50 = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib are used to treat certain forms of cancer, including non-small cell lung cancer. | | Uses | Erlotinib D6 HCl is a Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, Antineoplastic.;Labeled Erlotinib, intended for use as an internal standard for the quantification of Erlotinib by GC- or LC-mass spectrometry. |
| | Erlotinib D6 HCl Preparation Products And Raw materials |
|